Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Arvinas, Inc. - Common Stock (NQ:ARVN)

6.290 -0.350 (-5.27%)
Streaming Delayed Price Updated: 1:54 PM EDT, May 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arvinas, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Arvinas's Return on Invested Capital Insights
According to Benzinga Pro data, Arvinas (NASDAQ:ARVN) reported Q2 sales of $31.30 million. Earnings fell to a loss of $70.00 million, resulting in a 10.41% decrease from last quarter. 
Via Benzinga
Sanofi's Breast Cancer Drug Fallout 'Creates Buying Opportunity' For This Stock
According to Oppenheimer analyst, the fallout of Sanofi SA's (NASDAQ: SNY) amcenestrant creates a buying opportunity for Arvinas Inc (NASDAQ: ARVN)  
Via Benzinga
This Healthcare Stock Dipped Over 30%; Here Are 83 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Recap: Arvinas Q2 Earnings
  Arvinas (NASDAQ:ARVN) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Sanofi, Children's Place And Some Other Big Stocks Moving Lower On Wednesday
  Embark Technology, Inc. (NASDAQ: EMBK) fell 25.1% to $12.40. Embark Technology reported the completion of reverse stock split. 
Via Benzinga
Why Blue Water Vaccines Is Trading Higher By Around 80%, Here Are 61 Stocks Moving In Wednesday's Mid-Day Session
Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 79.5% to $4.57 after the company announced it plans to explore the potential development of a novel monkeypox vaccine using its norovirus... 
Via Benzinga
7 Analysts Have This to Say About Arvinas
Arvinas (NASDAQ:ARVN) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Analyst Ratings for Arvinas
Arvinas (NASDAQ:ARVN) has observed the following analyst ratings within the last quarter: 
Via Benzinga
8 Analysts Have This to Say About Arvinas
  Over the past 3 months, 8 analysts have published their opinion on Arvinas (NASDAQ:ARVN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Do You Have Biotech FOMO? It Might Be Time To Pay Attention To These Names
Biotech stocks continued going gangbusters Wednesday. Here's why, experts say. 
Via Investor's Business Daily
Do You Have Biotech FOMO? Why Cogent, Arvinas And Others Are Flying
Biotech stocks continued going gangbusters Wednesday. Here's why, experts say. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For May 9, 2022
Upgrades 
Via Benzinga
Arvinas: Q1 Earnings Insights
Arvinas (NASDAQ:ARVN) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Expert Ratings For Arvinas
Arvinas (NASDAQ:ARVN) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Arvinas: Q4 Earnings Insights
Arvinas (NASDAQ:ARVN) reported its Q4 earnings results on Monday, February 28, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 21, 2022
Upgrades 
Via Benzinga
What 6 Analyst Ratings Have To Say About Arvinas
Over the past 3 months, 6 analysts have published their opinion on Arvinas (NASDAQ:ARVN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022
Upgrades 
Via Benzinga
Arvinas Earnings Perspective: Return On Capital Employed
Benzinga Pro data, Arvinas (NASDAQ:ARVN) reported Q4 sales of $26.30 million. Earnings fell to a loss of $53.00 million, resulting in a 13.35% decrease from last quarter. In Q3,... 
Via Benzinga
Where Arvinas Stands With Analysts
Arvinas (NASDAQ:ARVN) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2... 
Via Benzinga
3 Stocks To Double Down On In 2022
The markets are entering somewhat uncertain territory, as the S&P 500 recently experienced its 39th correction since the beginning of 1950 due to a combination... 
Via Benzinga
Arvinas Highlights New ARV-110 Data In Prostate Cancer Patients
Arvinas Inc (NASDAQ: ARVN) announced the presentation of new data from completed Phase 1 dose-escalation and ongoing Phase 2 ARDENT expansion cohort with... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2022
Upgrades According to Gordon Haskett, the prior rating for Williams-Sonoma Inc (NYSE:WSM) was changed from Hold to Accumulate. Williams-Sonoma earned $3.32 in the third quarter,... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2022
Upgrades For Rocket Companies Inc (NYSE:RKT), JP Mo... 
Via Benzinga
5 Stocks Insiders Are Selling
When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to... 
Via Benzinga
Arvinas, Pfizer's ARV-471 Shows Clinical Benefit Rate Of 40% In Pretreated Breast Cancer Patients
Arvinas Inc (NASDAQ: ARVN) and Pfizer Inc (NYSE: PFE) posted updated data from Phase 1 dose-escalation trial of ARV-471 for locally advanced or... 
Via Benzinga
The Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine Data, Halozyme To Buy Back Shares
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Angion Biomedica's ANG-3777 Does Not Meet Primary Endpoint In Mid-Stage... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 7, 2021
Upgrades For CarMax Inc (NYSE: 
Via Benzinga
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.